This article will be permanently flagged as inappropriate and made unaccessible to everyone. Are you certain this article is inappropriate? Excessive Violence Sexual Content Political / Social
Email Address:
Article Id: WHEBN0022602885 Reproduction Date:
NS-2359 (GSK-372,475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant,[1] but was discontinued in 2009 when phase II clinical trials turned up disappointing results and did not support further effort by the company.[1] NS-2359 was also in clinical trials for the treatment of ADHD,[2] phase II having been completed in 2007.[3] A trial exploring the effect of NS-2359 on cocaine-experienced individuals is currently ongoing.[4]
Another scientific article on NS-2359 was recently (2011) published.[5] As can be seen from reading the abstract to the citation, the compound failed to perform in clinical trials for the treatment of depression.
Diamond, Graphite, Solar system, Coal, /anolanthanide Chemistry
Oxygen, Fluorine, Argon, Nitrogen, Sulfur
Oxygen, Argon, Hydrogen, Helium, Gold
Nitrogen, Hydrogen, Helium, Sulfur, Fluorine
Cocaine, Iron, Zinc, Lysergic acid diethylamide, 5-Carboxamidotryptamine
Methamphetamine, Amphetamine, Cocaine, L-dopa, Carbon
Ergoline, Serotonin, Lysergic acid diethylamide, 5-Methoxytryptamine, Substituted tryptamine